UCB SA (UCB.BR) Stock Fundamental Analysis

Europe • Euronext Brussels • EBR:UCB • BE0003739530

264 EUR
-1 (-0.38%)
Last: Feb 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to UCB. UCB was compared to 55 industry peers in the Pharmaceuticals industry. UCB has only an average score on both its financial health and profitability. UCB is valued quite expensive, but it does show an excellent growth. These ratings could make UCB a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year UCB was profitable.
  • In the past year UCB had a positive cash flow from operations.
  • UCB had positive earnings in each of the past 5 years.
  • In the past 5 years UCB always reported a positive cash flow from operatings.
UCB.BR Yearly Net Income VS EBIT VS OCF VS FCFUCB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

  • UCB has a Return On Assets (7.75%) which is in line with its industry peers.
  • With a Return On Equity value of 13.76%, UCB perfoms like the industry average, outperforming 56.36% of the companies in the same industry.
  • UCB has a Return On Invested Capital (11.63%) which is in line with its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 14.21%.
  • The 3 year average ROIC (4.35%) for UCB is below the current ROIC(11.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROIC 11.63%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
UCB.BR Yearly ROA, ROE, ROICUCB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • UCB has a better Profit Margin (19.45%) than 74.55% of its industry peers.
  • In the last couple of years the Profit Margin of UCB has remained more or less at the same level.
  • UCB has a better Operating Margin (26.58%) than 63.64% of its industry peers.
  • UCB's Operating Margin has declined in the last couple of years.
  • UCB has a better Gross Margin (73.38%) than 61.82% of its industry peers.
  • In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
Industry RankSector Rank
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
UCB.BR Yearly Profit, Operating, Gross MarginsUCB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • UCB has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for UCB has been increased compared to 5 years ago.
  • UCB has a better debt/assets ratio than last year.
UCB.BR Yearly Shares OutstandingUCB.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
UCB.BR Yearly Total Debt VS Total AssetsUCB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 5.57 indicates that UCB is not in any danger for bankruptcy at the moment.
  • UCB's Altman-Z score of 5.57 is fine compared to the rest of the industry. UCB outperforms 78.18% of its industry peers.
  • The Debt to FCF ratio of UCB is 2.43, which is a good value as it means it would take UCB, 2.43 years of fcf income to pay off all of its debts.
  • UCB has a better Debt to FCF ratio (2.43) than 81.82% of its industry peers.
  • UCB has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • UCB has a better Debt to Equity ratio (0.29) than 70.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Altman-Z 5.57
ROIC/WACC1.47
WACC7.89%
UCB.BR Yearly LT Debt VS Equity VS FCFUCB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.3 Liquidity

  • UCB has a Current Ratio of 1.35. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of UCB (1.35) is comparable to the rest of the industry.
  • UCB has a Quick Ratio of 1.01. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
  • UCB has a Quick ratio of 1.01. This is comparable to the rest of the industry: UCB outperforms 54.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.01
UCB.BR Yearly Current Assets VS Current LiabilitesUCB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.41% over the past year.
  • The Earnings Per Share has been decreasing by -0.86% on average over the past years.
  • The Revenue has grown by 25.56% in the past year. This is a very strong growth!
  • UCB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.60% yearly.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%

3.2 Future

  • The Earnings Per Share is expected to grow by 28.44% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, UCB will show a quite strong growth in Revenue. The Revenue will grow by 15.09% on average per year.
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y28.44%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.09%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
UCB.BR Yearly Revenue VS EstimatesUCB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B
UCB.BR Yearly EPS VS EstimatesUCB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 41.12, which means the current valuation is very expensive for UCB.
  • Compared to the rest of the industry, the Price/Earnings ratio of UCB indicates a slightly more expensive valuation: UCB is more expensive than 63.64% of the companies listed in the same industry.
  • UCB's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 28.23.
  • UCB is valuated quite expensively with a Price/Forward Earnings ratio of 25.67.
  • Based on the Price/Forward Earnings ratio, UCB is valued a bit more expensive than the industry average as 63.64% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.01, UCB is valued at the same level.
Industry RankSector Rank
PE 41.12
Fwd PE 25.67
UCB.BR Price Earnings VS Forward Price EarningsUCB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, UCB is valued a bit more expensive than the industry average as 61.82% of the companies are valued more cheaply.
  • UCB's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 43.33
EV/EBITDA 21.18
UCB.BR Per share dataUCB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • UCB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of UCB may justify a higher PE ratio.
  • A more expensive valuation may be justified as UCB's earnings are expected to grow with 38.91% in the coming years.
PEG (NY)0.68
PEG (5Y)N/A
EPS Next 2Y43.7%
EPS Next 3Y38.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • UCB has a yearly dividend return of 0.36%, which is pretty low.
  • UCB's Dividend Yield is slightly below the industry average, which is at 1.94.
  • Compared to an average S&P500 Dividend Yield of 1.79, UCB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.36%

5.2 History

  • The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
UCB.BR Yearly Dividends per shareUCB.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • UCB pays out 19.82% of its income as dividend. This is a sustainable payout ratio.
  • UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
UCB.BR Yearly Income VS Free CF VS DividendUCB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
UCB.BR Dividend Payout.UCB.BR Dividend Payout, showing the Payout Ratio.UCB.BR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

UCB SA

EBR:UCB (2/11/2026, 7:00:00 PM)

264

-1 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)02-26
Inst Owners41.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap51.35B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts76
Price Target275.68 (4.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.36%
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.12%
PT rev (3m)9.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.55%
EPS NY rev (3m)3.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.84%
Valuation
Industry RankSector Rank
PE 41.12
Fwd PE 25.67
P/S 7.5
P/FCF 43.33
P/OCF 32.58
P/B 5.3
P/tB 47.24
EV/EBITDA 21.18
EPS(TTM)6.42
EY2.43%
EPS(NY)10.28
Fwd EY3.9%
FCF(TTM)6.09
FCFY2.31%
OCF(TTM)8.1
OCFY3.07%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.68
PEG (5Y)N/A
Graham Number84.8
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROCE 13.73%
ROIC 11.63%
ROICexc 13.71%
ROICexgc 58.2%
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
FCFM 17.3%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Debt/EBITDA 1.15
Cap/Depr 61.48%
Cap/Sales 5.71%
Interest Coverage 16.4
Cash Conversion 64.17%
Profit Quality 88.96%
Current Ratio 1.35
Quick Ratio 1.01
Altman-Z 5.57
F-Score9
WACC7.89%
ROIC/WACC1.47
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y28.44%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.09%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year162.81%
EBIT Next 3Y59.8%
EBIT Next 5Y40.91%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%

UCB SA / UCB.BR FAQ

What is the fundamental rating for UCB stock?

ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.


Can you provide the valuation status for UCB SA?

ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UCB.BR). This can be considered as Overvalued.


Can you provide the profitability details for UCB SA?

UCB SA (UCB.BR) has a profitability rating of 6 / 10.


What are the PE and PB ratios of UCB SA (UCB.BR) stock?

The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 41.12 and the Price/Book (PB) ratio is 5.3.


What is the earnings growth outlook for UCB SA?

The Earnings per Share (EPS) of UCB SA (UCB.BR) is expected to grow by 60.25% in the next year.